Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 102Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Ovarian Neoplasms 6Neoplasm Metastasis 6Breast Neoplasms, Male 6Neoplasms 5Glioblastoma 5Central Nervous System Neoplasms 5Prostatic Neoplasms 4Gliosarcoma 4Inflammatory Breast Neoplasms 3Glioma 3Brain Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Glioma, Subependymal 2Fallopian Tube Neoplasms 2Ependymoma 2Breast Cancer Female 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Risk Reduction Behavior 1

Interventions

prexasertib 1Zoledronic Acid 1Tamoxifen 1Docetaxel 1Carboplatin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Breast and Ovarian Cancer Syndrome × Tamoxifen × Clear all
NCT00253539 2011-04-13

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

The Cleveland Clinic

Phase 2 Completed
3 enrolled
BreastGynecologic

Breast Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡